A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab Formulated with Berahyaluronidase Alfa
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Nab-paclitaxel
BIOLOGICAL: Pembrolizumab
DRUG: Filgrastim
DRUG: Pegylated filgrastim

Sponsor

Merck Sharp & Dohme LLC